Alcon, a worldwide leader in eye care and a Novartis division, has released its Online Toric IOL Calculator, which was developed for the use of cataract surgeons who are treating patients with corneal astigmatism. Read More »

Crown Bioscience, a subsidiary of Crown Bioscience International and a worldwide global drug discovery and development services company that provides translational platforms that improve the research of oncology and metabolic diseases, has named Dr. Jean Pierre Wery its CEO. Read More »

Argentina's regulatory body has approved Hemispherx Biopharma's New Drug Application for the commercial sale of rintatolimod. Read More »

Akebia Therapeutics Inc. and Otsuka Pharmaceutical Co. Ltd. recently entered a collaboration and license agreement in the U.S. for vadadustat, an oral hypoxia-inducible factor stabilizer in development for the treatment of anemia associated with chronic kidney disease Read More »

Mylan N.V. and Biocon Ltd. released results of their Heritage Study in the Journal of the American Medical Association, showing positive indications for MYL-1401O, the proposed biosimilar trastuzumab co-developed by Mylan and Biocon. Read More »

Incyte Corp. and Merus N.V. have a new partnership to study and develop a platform around bispecific antibodies using Merus’ proprietary Biclonics technology platform. Read More »

CVS Health is sponsoring Star-Spangled Babies, a baby shower program created by national nonprofit Operation Homefront, which provides short- and long-term support for military parents. Read More »

Prime Therapeutics LLC, a pharmacy benefit manager with more than 22 million customers across the nation, recently named John Drakulich as its new chief sales officer. Read More »

The National Association of Chain Drug Stores has issued a letter to the governors of all 50 states calling for pharmacy patient care to be a top priority in new health care policies in 2017. Read More »

Alcon, a division of Novartis that specializes in eye care, has received approval from the U.S. Food and Drug Administration for AcrySof IQ ReSTOR +3.0D Multifocal Toric Intraocular Lens (IOL), which was developed to treat presbyopia and pre-existing corneal astigmatism. Read More »

Teva Pharmaceuticals Industries' negotiations regarding the violation of the Foreign Corrupt Practices Act have concluded with a resolution of investigations in Ukraine, Mexico and Russia, where the subsidiary pleaded guilty. Read More »

The National Association of Chain Drug Stores, the National Community Pharmacists Association, the American Pharmacists Association and the National Alliance of State Pharmacy Associations have collaborated to send a letter to the incoming Donald Trump administration in that outlines necessary steps that will leverage pharmacy patient care and cut costs resulting from untreated conditions. Read More »

A $1.15 per share dividend was recently declared by Amgen's Board of Directors for the first quarter of next year. Read More »

Pharmacists ranked second behind only nurses in the 2016 Honesty and Ethics survey conducted by Gallup. Read More »

Dr. Giovanni Caforio has been named the Chairman of the Board for Bristol-Myers Squibb's board of directors, effective May 2 at the annual shareholder’s meeting. Read More »

Concert Pharmaceuticals' Phase 2 clinical trial taking place in the United States and involving CTP-656, also known as deuterated ivacaftor, has been initiated. Read More »

Endo International has appointed Patrick Barry as U.S. Branded Pharmaceuticals’ new senior vice president and Matthew Davis as the new senior vice president of research and development at Branded. Read More »

CVS Health President and CEO Larry Merlo recently announced that the CVS Health Charity Classic has surpassed the $20 million milestone in total contributions. Read More »

Tocagen's Phase 2/3 Toca 5 clinical trial has begun enrolling patients in Israel as enrollment in the United States and Canada continues. Read More »

Portola Pharmaceuticals has signed a $50 million loan agreement with Bristol-Myers Squibb and Pfizer that gives Portola supplementary funds to allow for the development and clinical trials of AndexXa. Read More »